GlassScriptPhysician profile
Deborah A Ronco
NPI 1043269830
$3,933.87
in general payments reported to CMS, 2019-2025
38 companies · $503 in 2025
The $503 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $185 · 2021: $589 · 2022: $815 · 2023: $744 · 2024: $703 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.76 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $789.09 | 2019-2025 | Liletta, Lo Loestrin Fe, Orilissa |
| Therapeuticsmd, INC. | $279.65 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $250.29 | 2021-2025 | |
| Hologic Sales and Service, LLC | $241.50 | 2019-2025 | Fluent Fluid Management System, Novasure, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Biogen, INC. | $236.44 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $228.12 | 2019-2025 | Slynd |
| Agile Therapeutics, INC. | $182.95 | 2021-2022 | |
| Pfizer INC. | $166.29 | 2020-2025 | |
| Medtronic, INC. | $136.38 | 2023 | V-Loc 180 |
| Myovant Sciences INC. | $112.66 | 2021-2022 | |
| Astellas Pharma US INC | $110.82 | 2019-2025 | Veozah |
| Axonics, INC. | $109.62 | 2022-2024 | Axonics, Bulkamid |
| Bayer Healthcare Pharmaceuticals INC. | $107.92 | 2019-2024 | |
| Coopersurgical, INC. | $105.38 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Avion Pharmaceuticals | $77.06 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $72.30 | 2023-2025 | Myfembree |
| Boston Scientific Corporation | $66.63 | 2025 | Axonics |
| Organon LLC | $57.22 | 2024-2025 | Nexplanon |
| Novo Nordisk INC | $56.86 | 2019-2022 | |
| Duchesnay USA Incorporated | $51.60 | 2019 | |
| Millicent US INC | $45.01 | 2024-2025 | Intrarosa |
| Kerecis Limited | $43.86 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Exact Sciences Corporation | $41.02 | 2023-2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $40.39 | 2023-2025 | Accrufer |
| Smith+Nephew, INC. | $38.33 | 2021-2023 | Renasys Touch, Pico 7 |
| Terumo Medical Corporation | $37.87 | 2024 | Hydropearl |
| Channel Medsystems, INC. | $32.57 | 2022-2023 | |
| Minerva Surgical, INC | $26.73 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $25.58 | 2019 | |
| Meditrina | $25.14 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.95 | 2019 | |
| Merck Sharp & Dohme LLC | $19.26 | 2024 | Gardasil, Gardasil 9 |
| Amag Pharmaceuticals, INC. | $18.98 | 2019 | |
| Gilead Sciences, INC. | $18.94 | 2025 | |
| Aspira Women'S Health INC | $18.23 | 2024 | Ova1 |
| Covidien LP | $13.95 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $12.89 | 2023 | Vivjoa |
| Lilly USA, LLC | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Ronco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.